Abstract Minimizing endogenous estrogen production and activity in women at high risk for breast cancer is a prominent approach to prevention of the disease. A number of clinical trials have shown that the administration of selective-estrogen receptor modulators or aromatase inhibitors significantly reduces the incidence of breast cancer in healthy women. Unfortunately, these drugs often produce adverse effects on the quality of life and are, therefore, poorly accepted by many women, even those who are at high risk for breast cancer. We propose a novel alternative approach to decreasing estrogen production: suppression of ovarian synthesis of the androgen precursors of estrogens by administration of long-acting gonadotropinreleasing hormone analogs to women with ovarian stromal hyperplasia. The specific target population would be elderly postmenopausal women, at increased risk of breast cancer, and with high blood levels of testosterone, marker of ovarian hyperandrogenemia, and recognized factor of risk for breast cancer. Testosterone levels are measured at baseline to identify women at risk and during the follow-up to evaluate the effectiveness of therapy. The postmenopausal ovary is an important source of excessive androgen production which originates from the ovarian interstitial cell hyperplasia frequently present in breast cancer patients. We propose to counter the source of androgen excess in women with ovarian stromal hyperplasia, thus reducing the substrate for estrogen formation without completely inhibiting estrogen synthesis. Available evidence indicates that gonadotropin-releasing hormone analogs can be safely used for breast cancer prevention in postmenopausal women.
Introduction
A large body of evidence points to estrogens as promoters of breast cancer development. This has led to attempt at cancer prevention through diminution of the impact of estrogen on the breast, either by administration of selective-estrogen receptor modulators, such as tamoxifen or raloxifen, which block the binding of estrogens to their cellular receptors or by administration of aromatase inhibitors, such as exemestane, anastrozole, or letrozole, which inhibit the synthesis of estrogens from their androgen precursors. Clinical trials have shown that applying this approach to women at high risk for breast cancer does indeed reduce the incidence of the disease [1] [2] [3] [4] [5] [6] . Unfortunately, these drugs often produce adverse effects on the quality of life, with musculoskeletal, vasomotor, and gynecological symptoms resulting from acutely decreased levels of estrogen [1] [2] [3] [4] [5] [6] . As a consequence, they have been poorly accepted by many women [5, 6] , even those who are at high risk for breast cancer according to risk prediction models [7] [8] [9] [10] .
In the present paper, we propose a novel alternative approach to breast cancer prevention that is virtually devoid of severe adverse events, namely suppression of ovarian production of the androgen precursors of estrogen by administration of long-acting gonadotropin-releasing hormone (GnRH) analogs, which inhibit the secretion of luteinizing hormone (LH), the necessary stimulus to ovarian androgen production. That this might be an effective approach was suggested by the extensive evidence that women with breast cancer often have interstitial cell hyperplasia of the ovaries, with resulting increased synthesis of androgens, which is often reflected in elevated blood testosterone levels [11] . Determining the blood testosterone levels of potential patients would delineate the women with ovarian hyperandrogenemia, who would be candidates for our proposed approach. The prime target population would be elderly postmenopausal women, since breast cancer incidence increases with age and reaches its maximum around the age of 70 years [12, 13] .
The rationale of our proposal is that the correction of the basic endocrine abnormality responsible of excessive androgen production will reduce estrogen formation, thus preserving breast epithelium from excessive estrogen stimulation. Ovarian hyperandrogenemia can be detected by measurement of serum testosterone levels and can be corrected by administration of GnRH analogs. In contrast, we cannot distinguish whether elevated serum estradiol levels mainly derive from increased conversion of ovarian androgen precursors (testosterone and androstenedione) or of adrenal androgen precursors [dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulfate (DHEAS), and androstenedione]: the different origin would require different therapeutic approaches.
In the next section, we describe the statement of our proposal and discuss the endocrine function of the postmenopausal ovary, the identification of women at increased risk, the tolerability and side effects of GnRH analogs, and the antiproliferative effect commonly attributed to androgens.
Discussion
Our proposal develops from the evidence that aromatization of androgen precursors, androstenedione, and testosterone, is an obligatory step in the synthesis of estrogens, estrone, and estradiol, respectively [14] ; high circulating androgen levels are a known factor of risk for postmenopausal breast cancer that can stimulate cancer growth by conversion into estrogens [15] [16] [17] ; the postmenopausal ovary is an important source of excessive androgen production which originates from the ovarian interstitial cell hyperplasia frequently present in breast cancer patients [11] .
We assume that antiestrogens are effective in countering increased estrogen synthesis and activity, which are consequences of excessive androgen production, and suggest directly countering the source of androgen excess in women with ovarian stromal hyperplasia, thus reducing the substrate for estrogen formation without completely inhibiting estrogen synthesis. Suppression of ovarian androgen production can be accomplished by administering long-acting GnRH analogs, which induce medical castration by inhibiting the synthesis of gonadotropins. The target population includes healthy women in natural menopause, with intact ovaries, 60 years of age or older, at increased risk of breast cancer according to one of the validated risk prediction models or owing to high mammographic density, and with elevated serum testosterone levels. High serum testosterone levels are a good marker of excessive ovarian androgen production [11] and a recognized factor of risk for breast cancer [15] [16] [17] . The availability of a risk factor that is powerful and that can be corrected is useful to identify a distinct subset of women at risk, to evaluate the effectiveness of treatment, and to personalize the treatment schedule according to the necessities of each subject. Circulating testosterone levels should be regularly checked every six to twelve months in women to whom GnRH analogs are administered; the treatment should be interrupted when blood testosterone levels return to normal and should be resumed when they rise again after the initial decrease.
The androgen-excess theory, developed in studies by our group over the last 45 years [11] , suggests a central role for androgens in breast cancer development. Increased conversion into estrogens is the principal mechanism by which androgen excess stimulates estrogen receptor (ER)-positive tumors [18, 19] .
A series of prospective studies in healthy postmenopausal women have shown that elevated blood androgen levels are associated with increased risk of breast cancer [15] [16] [17] . In these same studies, increased risk of breast cancer was also found associated with high serum levels of estrogens, a finding consistent with increased formation of estrogens by women with high levels of their androgen precursors. Evidence that the effect of increased androgen levels in favoring the development of estrogen-dependent breast cancers is a direct one is provided by the finding of a strong relationship between blood testosterone levels and the ER content of tumors in contrast to the weak relationship of blood estradiol levels to ER content [20, 21] .
About 50 % of circulating testosterone is produced by the ovary and the adrenals; the remaining 50 % is produced in peripheral tissues by conversion from androstenedione [22, 23] . Androstenedione is synthesized in the ovary and the adrenals, and in peripheral tissues by conversion from adrenal androgen precursors, DHEA and DHEAS [22, 23] .
During a woman's lifespan, blood testosterone levels decrease with age from the twenties till just before menopause [24, 25] , do not change during the menopausal transition [25] [26] [27] and then increase slightly in the late postmenopausal years [27] [28] [29] . In contrast, the blood levels of DHEA and DHEAS decline steadily with age from the early twenties regardless of menopausal status [25, 26] .
The postmenopausal ovary continues to secrete large amounts of testosterone and moderate amounts of androstenedione and DHEA well into old age [22, 27, 28, 30, 31] ; the androgen production occurs in the interstitial cells of the ovarian stroma under the stimulus of LH [30, 32, 33] . Ovarian stromal hyperplasia is a characteristic feature of breast cancer patients, as was reported for the first time by Sommers and Teloh in 1952 [34] . Our early studies in the 1970s [11] showed that such hyperplasia was constantly present in the ovaries of breast cancer patients with supranormal urinary testosterone excretion who underwent oophorectomy, either prophylactically, to prevent disease progression, or therapeutically, for treatment of metastases. In those patients, independent of their menopausal status, testosterone levels usually reverted to normal after the ovaries were removed, and metastases often regressed [11] . Different degrees of stromal hyperplasia, mild, medium, and severe have been frequently found in postmenopausal women oophorectomized for gynecological disorders, and the concentrations of testosterone and androstenedione in the ovarian veins were found to be positively associated with the degree of stromal hyperplasia [35] [36] [37] . A significant reduction of testosterone and androstenedione circulating levels has been constantly reported after oophorectomy [27, 28, 30, 31, [35] [36] [37] .
A study of BRCA1 and BRCA2 mutation carriers showed a highly significant reduction of breast cancer risk in women who had oophorectomy after natural menopause, whereas women with natural menopause who were not oophorectomized showed no such effect [38] ; the authors suggested that the reduction of circulating testosterone levels after oophorectomy might account for its protective effect [38] . In a recent study [39] , blood levels of androgens and estrogens were measured in a group of women who underwent natural menopause without oophorectomy and in two groups of women who underwent oophorectomy either at premenopausal age or after natural menopause. Significantly lower testosterone levels were found in both oophorectomized groups than in women with intact ovaries, while the levels of estradiol, estrone, estrone-sulfate, and DHEAS did not differ among the three groups [39] .
It appears, therefore, that the postmenopausal ovary is an endocrine organ that produces androgens well into old age; that ovarian stromal hyperplasia increases androgen production; that blood testosterone level is a good marker of ovarian androgen production; and that oophorectomy after the natural menopause significantly reduces the blood testosterone levels and may be protective against breast cancer.
Several breast cancer risk prediction models are actually available to identify women at high risk [7] [8] [9] [10] . In these models, risk is calculated by awarding a score to known risk factors including age, reproductive, and family history-previous breast biopsies and others [7] [8] [9] [10] . Although effective in predicting absolute risk, these models have limited ability to discriminate between women who will develop breast cancer and those who will not [8] .
Candidates for the prevention study that we propose would also be identified by mammographic density for three principal reasons: mammographic density is one of the most powerful factors of risk for breast cancer [40] ; combined evaluation of mammographic density with circulating levels of estradiol or testosterone identifies subgroups of postmenopausal women at a particularly high risk of breast cancer [41, 42] , who would be optimal candidates for prevention studies; breast density is a modifiable factor of risk which might be used as a ''surrogate marker of breast cancer'' for evaluating the effectiveness of therapy in clinical studies after a short period of observation [40, 43] .
Our proposal applies only to women with ovarian hyperandrogenemia, who may be identified by high testosterone levels. An estimate of the number of cancers that could be prevented by correcting androgen excess in otherwise healthy women can be obtained by data of our studies in a cohort of 534 postmenopausal breast cancer patients [21] . High testosterone levels were found in about half of ER-positive patients and in about 6 % of ER-negative patients of our cohort [18, 44] . It has been reported [45] that a single measurement of testosterone can predict breast cancer risk for up to 20 years in healthy women; therefore, we can assume that the high testosterone levels detected in patients of our cohort were present before the diagnosis of cancer and contributed to the development of about 50 % of ER-positive tumors.
We suggest selecting normal postmenopausal women with elevated serum testosterone levels for prophylactic treatment with GnRH analogs, and in order to do this, we need to determine the best cut-off value between normal testosterone levels and elevated levels. The choice of the cut-off value must take into account several factors, such as the method used for measurement of testosterone levels, the population upon which the normal assay ranges are established and many other variables. Therefore, actually there is not a general agreement about the cut-off value of testosterone that definitely identifies its normal values in the general population.
Prospective studies in healthy postmenopausal women have reported an association of elevated levels of estrogens and androgens with increased risk of breast cancer, regardless of the method used for steroid quantization, whether direct radioimmunoassay (RIA), RIA after prior extraction and purification of the sample, or mass spectrometry [46] . In prospective studies of postmenopausal breast cancer patients [44, 47, 48] , we measured blood testosterone levels by direct RIA and found that patients with levels above the median value for the group were at higher risk of relapse than patients below the median value. In those studies, carried out at different times and in different groups of breast cancer patients, the median value of blood testosterone concentration was consistently 0.40 ng/ ml, which corresponds to the lower boundary of the uppermost tertile in three hundred healthy postmenopausal women recruited in a previous study [49] . Although direct RIA may be appropriate for identifying women with elevated serum testosterone values in prospective studies, the method has been criticized for its lack of the accuracy and sensitivity required to measure the low blood testosterone levels commonly present in normal women and children [50] [51] [52] [53] . Methods using RIA after extraction and purification of the sample can measure testosterone with sensitivity and accuracy, but this procedure is labor-intensive and time-consuming [51] . Currently, liquid chromatography tandem mass spectrometry is the preferred method for measurement of low testosterone and estradiol concentrations [53] and should be the method of choice in future studies for identifying women with high testosterone levels in the general population.
Long-acting GnRH analogs inhibit the pituitary synthesis of the gonadotropins, LH and follicle stimulating hormone (FSH), and thereby deprive the ovaries of the necessary stimulation for androgen and estrogen production. Giving these agents is commonly referred to as ''medical oophorectomy''; the effect is reversible when the GnRH analog treatment is stopped.
The usual use of these agents is in premenopausal women with gynecological disorders such as uterine fibroids or endometriosis, in men with prostate cancer, and in premenopausal early breast cancer patients as adjuvant therapy of ER-positive tumors. They have also been used in premenopausal women with metastatic breast cancer, where they achieve responses similar to those of surgical oophorectomy, but produce the same estrogen-deprivation side effects as the surgical procedure. A few studies have examined the effect of the GnRH analogs in unselected postmenopausal women with metastatic breast cancer [54] [55] [56] . No significant adverse reactions, in particular no hot flushes, were observed [54] [55] [56] , but the therapeutic response in these unselected patients was low (16-20 %) [55] , so treatment with the analogs has not been recommended by these authors. On the other hand, if the GnRH analog treatment were offered to postmenopausal women with elevated testosterone levels, one might expect a much higher percentage of responders, as suggested by findings of our early studies in metastatic breast cancer patients with supranormal urinary testosterone values [11] .
Adverse effects of GnRH analogs in premenopausal women are the consequence of premature ovarian failure induced by the therapy. They are generally of low or moderate intensity but a high intensity of one or more menopause-like disturbances has been reported in 3.9-16.3 % of premenopausal breast cancer patients treated with the analogs [57] [58] [59] [60] . Such negative side effects should not occur in women who are already postmenopausal, according to the few data that we have found in the literature [53, 54, 61] .
Decrease of bone mineral density and increased risk of osteoporosis are common consequences of ovarian suppression in premenopausal women. FSH stimulates aromatase activity in the ovarian follicles, the principal site of estrogen production in premenopausal women. After the menopause, ovarian follicles disappear and estrogen production occurs only in peripheral tissues, including the adipose tissue that is the main source of estrogens at this age. In the adipose tissue, aromatase activity is unaffected by FSH and is stimulated by glucocorticoids [62] [63] [64] [65] . Therefore, inhibition of the synthesis of gonadotropins by GnRH analogs does not influence estrogen production in postmenopausal women and should not adversely affect the bones. Nevertheless, bone mineral density should be evaluated at baseline and regularly checked during the follow-up of a breast cancer prevention study in postmenopausal women.
Injection-site and allergic reactions of low or moderate intensity were seen in 5-7 % of premenopausal early breast cancer patients treated with GnRH analogs [60] . Severe events were virtually absent (0.5 % of allergic reaction of 3rd or 4th degree) [60] .
We are aware that androgens exert an antiestrogen, growth-inhibitory effect in normal breast epithelium and that a protective role of androgens has been postulated for ER-positive breast cancers on the basis of epidemiological and experimental evidence. These findings might create concern for our proposed approach to ER-positive breast cancer prevention but we wish to emphasize that our objective is not to totally abrogate androgenic activity, for example using antiandrogens, but to normalize high serum androgen levels in women with excessive androgen production. It is unlikely that normalization of androgen production will inhibit the normal regulatory effect of androgens on breast epithelium-on the contrary, cancer development may be favored more by the untreated endocrine abnormality (ovarian interstitial cells hyperplasia) than by its correction (medical oophorectomy).
Our proposal is addressed to prevention of ER-positive breast cancer and takes into account the paradoxical effect of androgens, both stimulating and inhibiting mammary epithelial cells growth. The mechanism by which androgen excess stimulates ER-positive tumors has been previously reported in detail [18] and can be summarized as follows: within the cancer cell, high androgen levels in the presence of high aromatase activity induce increased estrogen formation that stimulates cell proliferation by binding to ER. At the same time, high intratumor androgen levels favor increased conversion of testosterone into the stronger (and non aromatizable) DHT which up-regulates AR expression. The increased synthesis of DHT and AR overexpression can be interpreted as an attempt to counter the stimulatory effect of increased estrogen production [67, 68] . It is not surprising that most of the preclinical studies in ER-positive breast cancer cell lines have shown an antiproliferative effect of androgens and that most clinical studies have reported a positive association between AR-positivity and improved clinical outcomes [69, 70] . The dual role of androgens in ER-positive cancers accounts for their protective effect shown in preclinical and clinical studies, explains the association of high androgen serum levels with increased risk of developing cancer in healthy women, and supports the proposal to inhibit excessive androgen production for cancer prevention.
Interesting data on the role of androgens in ER-positive breast cancers have been obtained by studies of intrinsic and acquired resistance to treatment with antiestrogens. AR and epidermal growth factor receptor (EGFR) overexpression are recognized mechanisms of endocrine resistance [71] [72] [73] [74] [75] which suggests the involvement of androgens both as promoters of AR overexpression and as stimulators of EGF synthesis and function. Mechanisms of intrinsic resistance to antiestrogens are present before the clinical onset of the disease. Inhibition of excessive androgen production may counter the action of AR-driven and EGFR-driven pathways that stimulate breast epithelial cells proliferation as an alternative to the classical estrogen/ER pathway.
Benign breast disease (BBD) is an important breast cancer risk factor that is frequently present in healthy women. BBD is commonly divided into nonproliferative disease and proliferative disease that can progress from simple hyperplasia to atypical hyperplasia to in situ carcinoma [76] . Ductal carcinoma in situ (DCIS) is the most common (80-90 %) type of in situ carcinoma and is regarded as the immediate precursor of most infiltrating cancers, with which it shares genetic [76] and endocrine abnormalities [77] [78] [79] [80] [81] [82] [83] . The majority of DCIS are of low and intermediate grade (G1, G2), co-express ER and AR, and lack human epidermal growth factor receptor 2 (HER2) [78, [81] [82] [83] . The analogies with ER-positive infiltrating carcinoma suggest that androgen excess plays the same role in both these conditions and that the majority of DCIS might benefit from normalization of excessive androgen production. This conclusion can be extended to other subtypes of premalignant lesions, such as atypical hyperplasia and lobular carcinoma in situ, that may have the same characteristics (ER-and AR-positivity).
About 25 % of DCIS are ER-negative, predominantly AR-positive, HER2-positive [77] , and of high grade (G3) [78, 82] . The role of androgens in ER-negative DCIS is debated but stimulation of tumor growth by binding to AR or by increased production of EGF can be hypothesized in some cases. In this subtype, correction of excessive androgen production might be protective.
ER-negative tumors are a very heterogeneous class of cancers: AR are expressed in about half of them and may have either inhibitory or stimulatory effects on different subtypes [69, 70, 84] . A pro-proliferative role for AR signaling has been generally recognized in molecular apocrine tumors (ER-negative/AR-positive), which are often enriched by HER2 overexpression (ER-negative, ARpositive, and HER2-positive) but may be HER2-negative in a small percentage of cases (AR-positive and triple negative subtype) [69, 70, 84] . AR-targeting therapy has been proposed for ER-negative/AR-positive tumors and two clinical trials are underway to test the effectiveness of antiandrogens in patients with metastatic ER-negative/ARpositive tumors (reported in [69, 70] ). However, although most studies on molecular apocrine cell lines reported a pro-proliferative effect of AR, others have shown an ARBreast Cancer Res Treat (2016) 158:553-561 557 mediated antiproliferative effect, suggesting that AR expression may be insufficient to identify ER-negative patients suitable for AR-targeting therapy [69, 70] . Summing up the data reported above, normalization of excessive androgen production seems to be a suitable and safe approach to prevention of ER-positive cancer, which is the objective of our proposal, and might also be effective in preventing some ER-negative cancers, in subjects with elevated serum testosterone levels. It is unlikely that inhibition of androgen excess would stimulate growth of ERnegative subtypes because our approach permits peripheral production of active androgens from adrenal precursors (DHEA, DHEAS, and androstenedione) to continue. For additional protection, we suggest to stop the administration of GnRH analogs when blood testosterone levels return to normal and to resume the treatment when they rise again, a strategy that will protect against the risk of deficient androgenic activity.
Conclusion
We propose a novel approach to breast cancer prevention by administering a long-acting GnRH analog to postmenopausal healthy women with high serum testosterone levels. Our objective is to reduce the substrate for estrogen formation thus preserving breast epithelium from excessive estrogen stimulation without completely inhibiting estrogen synthesis that persists at a lower level by conversion from adrenal androgen precursors. Candidates for our proposed approach are women at increased risk of breast cancer identified by validated risk prediction models, by increased mammographic density, and by high testosterone levels. Mammographic density and testosterone levels are independent risk factors for postmenopausal breast cancer [41, 42] : the combined evaluation of these two parameters identifies a group of women at a particularly high risk of breast cancer. Both elevated testosterone levels and mammographic density are modifiable risk factors [43, 66] which could be employed to evaluate effectiveness of treatment.
Overall, the available data suggest that GnRH analogs can be used safely and with few side effects for breast cancer prevention in postmenopausal women, but the paucity of information available about the results of such use mandates caution and close follow-up.
In conclusion, we suggest the following approach: (1) Elderly postmenopausal women at high risk for breast cancer should be screened for elevated blood testosterone levels. (2) Since the source of such elevation is ovarian stromal hyperplasia, the women with high levels should be offered ''medical oophorectomy'' with long-acting GnRH analogs. (3) Testosterone levels should be measured during the treatment in order to evaluate its effectiveness and provide a rationale for continuing it. (4) Changes in mammographic density could be evaluated after about 2 years of therapy.
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